CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.84
1.66%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.09
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.81
Open* 1.78
1-Year Change* 368.42%
Day's Range* 1.77 - 1.85
52 wk Range 0.97-7.02
Average Volume (10 days) 36.23K
Average Volume (3 months) 6.22M
Market Cap 9.36M
P/E Ratio -100.00K
Shares Outstanding 4.52M
Revenue 3.75M
EPS -6.18
Dividend (Yield %) N/A
Beta 0.55
Next Earnings Date Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 1.84 0.06 3.37% 1.78 1.87 1.76
Apr 11, 2024 1.81 0.05 2.84% 1.76 1.84 1.76
Apr 10, 2024 1.78 0.00 0.00% 1.78 1.84 1.76
Apr 9, 2024 1.80 -0.02 -1.10% 1.82 1.84 1.80
Apr 8, 2024 1.84 0.02 1.10% 1.82 1.84 1.76
Apr 5, 2024 1.86 -0.03 -1.59% 1.89 1.94 1.81
Apr 4, 2024 1.86 -0.04 -2.11% 1.90 1.91 1.85
Apr 3, 2024 1.86 0.01 0.54% 1.85 1.91 1.81
Apr 2, 2024 1.82 0.01 0.55% 1.81 1.84 1.77
Apr 1, 2024 1.78 0.01 0.56% 1.77 1.79 1.73
Mar 28, 2024 1.76 -0.02 -1.12% 1.78 1.82 1.74
Mar 27, 2024 1.81 0.04 2.26% 1.77 1.81 1.74
Mar 26, 2024 1.81 -0.09 -4.74% 1.90 1.90 1.74
Mar 25, 2024 1.87 -0.05 -2.60% 1.92 1.92 1.76
Mar 22, 2024 1.82 0.06 3.41% 1.76 1.84 1.76
Mar 21, 2024 1.79 0.00 0.00% 1.79 1.90 1.74
Mar 20, 2024 1.82 0.02 1.11% 1.80 1.83 1.78
Mar 19, 2024 1.82 0.13 7.69% 1.69 1.82 1.68
Mar 18, 2024 1.69 -0.04 -2.31% 1.73 1.73 1.63
Mar 15, 2024 1.67 0.05 3.09% 1.62 1.76 1.58

Cytori Therapeutics Events

Time (UTC) Country Event
Thursday, April 18, 2024

Time (UTC)

14:00

Country

US

Event

Q1 2024 Plus Therapeutics Inc Earnings Release
Q1 2024 Plus Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Friday, April 19, 2024

Time (UTC)

14:00

Country

US

Event

Plus Therapeutics Inc Annual Shareholders Meeting
Plus Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, August 12, 2024

Time (UTC)

14:00

Country

US

Event

Q2 2024 Plus Therapeutics Inc Earnings Release
Q2 2024 Plus Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0.224 0 0.303 6.998 6.654
Revenue 0.224 0 0.303 6.998 6.654
Cost of Revenue, Total 2.373
Gross Profit 4.281
Total Operating Expense 19.936 12.492 9.887 10.655 19.352
Selling/General/Admin. Expenses, Total 10.238 6.853 6.406 5.29 8.357
Research & Development 9.698 5.323 2.7 5.365 8.622
Interest Expense (Income) - Net Operating
Unusual Expense (Income) 0 0.316 0.781 0
Operating Income -19.712 -12.492 -9.584 -3.657 -12.698
Interest Income (Expense), Net Non-Operating -0.563 -0.907 1.343 1.607 0.354
Other, Net 0 -1.233 -0.29
Net Income Before Taxes -20.275 -13.399 -8.241 -3.283 -12.634
Net Income After Taxes -20.275 -13.399 -8.241 -3.283 -12.634
Net Income Before Extra. Items -20.275 -13.399 -8.241 -3.283 -12.634
Net Income -20.275 -13.399 -8.241 -10.887 -12.634
Total Adjustments to Net Income 0 -0.554 -2.487
Income Available to Common Excl. Extra. Items -20.275 -13.399 -8.241 -3.837 -15.121
Income Available to Common Incl. Extra. Items -20.275 -13.399 -8.241 -11.441 -15.121
Diluted Net Income -20.275 -13.399 -8.241 -11.441 -15.121
Diluted Weighted Average Shares 1.75035 0.80599 0.2952 0.09227 0.01159
Diluted EPS Excluding Extraordinary Items -11.5834 -16.6244 -27.9163 -41.5835 -1304.59
Diluted Normalized EPS -11.5834 -16.2323 -25.2707 -41.5835 -1304.59
Total Extraordinary Items 0 -7.604
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 1.854 0.506 0.151 0.073 0
Revenue 1.854 0.506 0.151 0.073
Total Operating Expense 3.344 5.226 5.723 5.167 5.12
Selling/General/Admin. Expenses, Total 1.924 2.243 3.585 2.222 2.289
Research & Development 1.42 2.983 2.138 2.945 2.831
Operating Income -1.49 -4.72 -5.572 -5.094 -5.12
Interest Income (Expense), Net Non-Operating 0.008 -0.083 -0.086 -0.125 -0.162
Net Income Before Taxes -1.482 -4.805 -5.658 -5.219 -5.282
Net Income After Taxes -1.482 -4.805 -5.658 -5.219 -5.282
Net Income Before Extra. Items -1.482 -4.805 -5.658 -5.219 -5.282
Net Income -1.482 -4.805 -5.658 -5.219 -5.282
Income Available to Common Excl. Extra. Items -1.482 -4.805 -5.658 -5.219 -5.282
Income Available to Common Incl. Extra. Items -1.482 -4.805 -5.658 -5.219 -5.282
Diluted Net Income -1.482 -4.805 -5.658 -5.219 -5.282
Diluted Weighted Average Shares 2.50938 2.32013 2.24356 1.82954 1.48373
Diluted EPS Excluding Extraordinary Items -0.59058 -2.071 -2.52188 -2.85264 -3.55995
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.59058 -2.07014 -2.52188 -2.85264 -3.55995
Unusual Expense (Income) 0 0
Gain (Loss) on Sale of Assets 0 -0.002
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 21.817 19.724 9.175 19.825 9.648
Cash and Short Term Investments 18.12 18.4 8.346 17.552 5.261
Cash & Equivalents 18.12 18.4 8.346 17.552 5.261
Total Receivables, Net 0 1.313 0.178
Accounts Receivable - Trade, Net 0 1.169 0.178
Total Inventory 0 0.107 0.107
Other Current Assets, Total 0.007 0.059 0.04 4.102
Total Assets 23.867 21.981 12.105 23.229 23.991
Property/Plant/Equipment, Total - Net 1.572 1.818 2.456 2.96 2.299
Goodwill, Net 0.372 0.372 0.372 0.372 0.372
Intangibles, Net 0.094 0.051 0.086
Other Long Term Assets, Total 0.012 0.016 0.016 0.072 11.672
Total Current Liabilities 11.852 5.87 8.539 14.486 17.559
Payable/Accrued 0.245 2.777
Notes Payable/Short Term Debt 1.608 1.608 6.335 0 14.202
Current Port. of LT Debt/Capital Leases 0 0 0.01 11.18
Total Liabilities 17.422 11.145 9.074 22.069 18.766
Total Long Term Debt 3.786 5.005 0 0.008 0
Long Term Debt 3.786 5.005
Other Liabilities, Total 1.784 0.27 0.535 7.575 1.207
Total Equity 6.445 10.836 3.031 1.16 5.225
Preferred Stock - Non Redeemable, Net 0 0
Common Stock 0.034 0.016 0.007 0.004 0
Additional Paid-In Capital 473.596 457.73 436.535 426.426 418.39
Retained Earnings (Accumulated Deficit) -467.185 -446.91 -433.511 -425.27 -414.383
Other Equity, Total 0 1.218
Total Liabilities & Shareholders’ Equity 23.867 21.981 12.105 23.229 23.991
Total Common Shares Outstanding 2.2402 1.03405 0.44996 0.25872 0.01977
Property/Plant/Equipment, Total - Gross 3.532 3.233 3.843 3.981 0
Accrued Expenses 1.88 1.529 1.137 2.973 0
Other Current Liabilities, Total 0 0.122 0.023 0.006 0.58
Prepaid Expenses 3.697 1.317 0.77 0.813
Accumulated Depreciation, Total -1.96 -1.415 -1.387 -1.021
Accounts Payable 8.364 2.611 0.789 0.327
Capital Lease Obligations 0 0.008
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 11.584 12.364 13.629 21.817 20.879
Cash and Short Term Investments 11.006 10.895 12.723 18.12 20.266
Cash & Equivalents 11.006 10.895 12.723 18.12 20.266
Other Current Assets, Total 0.487 0.751 0.906 3.697 0.54
Total Assets 13.278 14.197 15.638 23.867 23.104
Property/Plant/Equipment, Total - Net 1.241 1.385 1.546 1.572 1.728
Goodwill, Net 0.372 0.372 0.372 0.372 0.372
Intangibles, Net 0.049 0.064 0.079 0.094 0.113
Other Long Term Assets, Total 0.032 0.012 0.012 0.012 0.012
Total Current Liabilities 10.538 11.399 12.796 11.852 7.42
Payable/Accrued 6.073 6.58 6.495 10.134 5.705
Accrued Expenses 0.117 0.11 0.107 0.11 0.107
Notes Payable/Short Term Debt 4.348 4.709 5.057 1.608 1.608
Current Port. of LT Debt/Capital Leases 0
Total Liabilities 10.656 11.535 12.962 17.422 11.7
Total Long Term Debt 0 0 0 3.786 4.108
Capital Lease Obligations
Other Liabilities, Total 0.118 0.136 0.166 1.784 0.172
Total Equity 2.622 2.662 2.676 6.445 11.404
Preferred Stock - Non Redeemable, Net 0
Common Stock 0.005 0.003 0.036 0.034 0.032
Additional Paid-In Capital 479.308 476.131 474.63 473.596 472.899
Retained Earnings (Accumulated Deficit) -476.691 -473.472 -471.99 -467.185 -461.527
Total Liabilities & Shareholders’ Equity 13.278 14.197 15.638 23.867 23.104
Total Common Shares Outstanding 4.52266 2.87962 2.40838 2.2402 2.17144
Long Term Debt 0 0 0 3.786 4.108
Total Receivables, Net 0.091 0.718 0.073
Other Current Liabilities, Total 1.137
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -20.275 -13.399 -8.241 -10.887 -12.634
Cash From Operating Activities -12.972 -10.28 -8.434 -5.906 -11.975
Cash From Operating Activities 0.619 0.395 0.366 0.896 2.004
Non-Cash Items 0.958 1.486 -0.678 5.023 -0.313
Cash Interest Paid 0.327 0.388 0.567 1.188 1.331
Changes in Working Capital 5.726 1.238 0.119 -0.938 -1.032
Cash From Investing Activities -0.759 -0.082 -0.493 5.57 -0.133
Capital Expenditures -0.509 -0.144 -0.493 -0.067 -0.133
Other Investing Cash Flow Items, Total -0.25 0.062 0 5.637 0
Cash From Financing Activities 13.451 20.416 -0.319 12.631 7.168
Financing Cash Flow Items 0 -1.598
Total Cash Dividends Paid
Issuance (Retirement) of Stock, Net 15.059 20.692 5.105 16.454 8.766
Issuance (Retirement) of Debt, Net -1.608 -0.276 -5.424 -3.823 0
Foreign Exchange Effects 0 -0.004 0.016
Net Change in Cash -0.28 10.054 -9.246 12.291 -4.924
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -4.805 -20.275 -14.617 -9.398 -4.116
Cash From Operating Activities -5.793 -12.972 -10.738 -6.516 -3.876
Cash From Operating Activities 0.158 0.619 0.46 0.302 0.147
Non-Cash Items 0.208 0.958 0.749 0.528 0.284
Cash Interest Paid 0.073 0.327 0.248 0.168 0.087
Changes in Working Capital -1.354 5.726 2.67 2.052 -0.191
Cash From Investing Activities -0.097 -0.759 -0.748 -0.715 -0.577
Capital Expenditures -0.097 -0.509 -0.498 -0.465 -0.327
Cash From Financing Activities 0.493 13.451 13.352 6.921 7.292
Issuance (Retirement) of Stock, Net 0.895 15.059 14.558 7.725 7.694
Issuance (Retirement) of Debt, Net -0.402 -1.608 -1.206 -0.804 -0.402
Net Change in Cash -5.397 -0.28 1.866 -0.31 2.839
Other Investing Cash Flow Items, Total 0 -0.25 -0.25 -0.25 -0.25

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cytori Therapeutics Company profile

About Plus Therapeutics Inc

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Plus Therapeutics Inc revenues decreased from $303K to $0K. Net loss increased 63% to $13.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 97% to $5.2M (expense), Change in fair value of liability instru decrease of 100% to $6K (income).

Equity composition

Common Stock $.001 Par, 02/11, 95M auth., 51,963,679 issd. Insiders own 14.62% IPO:N/A. 05/16, 1-for-15 reverse stock split.

Industry: Biotechnology & Medical Research (NEC)

4200 Marathon Blvd Ste 200
AUSTIN
TEXAS 78756-3433
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

US100

18,006.40 Price
-1.660% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,056.61 Price
+4.880% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,344.52 Price
-1.190% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.50

XRP/USD

0.50 Price
+14.480% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading